DAFTAR PUSTAKA

1. World Health Organization. Cancer [Internet]. [cited 2025 Apr 16]. Cited from: https://www.who.int/health-topics/cancer#tab=tab_1

2. National Cancer Institute. Cervix [Internet]. 2023. Cited from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/cervix

3. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021;149(4):778–89.

4. WHO. Indonesia Cervical Cancer Profile. World Heal Organ [Internet]. 2021;(2020):1. Cited from: hpvcentre.net/statistics/reports/IDN_FS.pdf

5. Josephine R. Fowler; Elizabeth V. Maani; Charles J. Dunton; David P. Gasalberti; Brian W. Jack. Cervical Cancer - StatPearls - NCBI Bookshelf [Internet]. 2023 [cited 2025 Apr 9]. Cited from: https://www.ncbi.nlm.nih.gov/books/NBK431093/

6. Cervical Cancer Causes, Risk Factors, and Prevention - NCI [Internet]. [cited 2025 Apr 10]. Cited from: https://www.cancer.gov/types/cervical/causes-risk-prevention

7. Miccò M, Lupinelli M, Mangialardi M, Gui B MR. Patterns of recurrent disease in cervical cancer. J Pers Med. 2022;12(5):755.

8. Li J, Liu G, Luo J, Yan S, Ye P, Wang J, et al. Cervical cancer prognosis and related risk factors for patients with cervical cancer: a long-term retrospective cohort study. Sci Rep [Internet]. 2022;12(1):1–11. Cited from: https://doi.org/10.1038/s41598-022-17733-8

9. Liu Y, Zhang N, Yang Q. Predicting the recurrence of usual-type cervical adenocarcinoma using a nomogram based on clinical and pathological factors: a retrospective observational study. Front Oncol. 2024;14(February):1–14.

10. Vebiyola W. Hubungan Usia Pertama Menikah Dan Paritas Dengan Kejadian Kanker Serviks Pada Wanita Usia Subur Di RSUP. M.Djamil Padang. Tugas Akhir. 2018;(35).

11. Argy G, Nuryanto KH, Hellyanti T. Prognostic Factors of Recurrent Cervical Cancer Stage IA2–IIA2: A Post-Surgical Treatment Analysis. Indones J Cancer. 2024 Dec 23;18(4):427–32.

12. WHO. Cancer [Internet]. 2025. Cited from: https://www.who.int/health-topics/cancer#tab=tab_1

13. National Cancer Institute. Cervical Cancer [Internet]. 2023. Cited from: https://www.cancer.gov/types/cervical

14. National Cancer Institute. Cervical Cancer Stages [Internet]. National Cancer Institute. 2022. Cited from: https://www.cancer.gov/types/cervical/stages

15. Fowler JR, Maani E V., Dunton CJ, Gasalberti DP, Jack BW. Cervical Cancer. Encycl Behav Med [Internet]. 2023 Nov 12 [cited 2025 Apr 9];350–1. Cited from: https://www.ncbi.nlm.nih.gov/books/NBK431093/

16. National Cancer Institute. Cervical Cancer Causes, Risk Factors, and Prevention - NCI [Internet]. National Cancer Institute. 2024 [cited 2025 Oct 4]. Cited from: https://www.cancer.gov/types/cervical/causes-risk-prevention

17. Sravani AB, Ghate V, Lewis S. Human papillomavirus infection, cervical cancer and the less explored role of trace elements. Vol. 201, Biological Trace Element Research. Springer; 2023. p. 1026–50.

18. Mathur A, Thakur S, Singh DAP. An Overview of Pathophysiology and Management of Cervical Cancer. Int J Pharm Sci Rev Res. 2024 Jul;84(7).

19. Cervical Cancer Symptoms - NCI [Internet]. [cited 2025 Apr 12]. Cited from: https://www.cancer.gov/types/cervical/symptoms

20. Dollin J. Preventing cervical cancer: Beyond following guidelines. C Can Med Assoc J. 2013;185(1):13–4.

21. Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: A systematic review and meta-analysis. Syst Rev. 2013;2(1).

22. Janicek M, Averette H. Cervical cancer: Prevention, diagnosis, and therapeutics. Lab Med. 2001;32(11):646–9.

23. Sachan P, Singh M, Patel M, Sachan R. A Study on Cervical Cancer Screening Using Pap Smear Test and Clinical Correlation. Asia-Pacific J Oncol Nurs. 2018 Jul 1;5(3):337–41.

24. McGraw SL, Ferrante JM. Update on prevention and screening of cervical cancer. World J Clin Oncol. 2014;5(4):744–52.

25. Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, et al. Cervical cancer: Screening, diagnosis and staging. J BUON. 2016;21(2):320–5.

26. Cervical Cancer Tests | How to Test For Cervical Cancer | American Cancer Society [Internet]. [cited 2025 Apr 12]. Cited from: https://www.cancer.org/cancer/types/cervical-cancer/detection-diagnosis-

staging/how-diagnosed.html

27. Cervical Cancer Treatment by Stage - NCI [Internet]. [cited 2025 Apr 26]. Cited from: https://www.cancer.gov/types/cervical/treatment/by-stage

28. Cervical Cancer Treatment - NCI [Internet]. [cited 2025 Apr 13]. Cited from: https://www.cancer.gov/types/cervical/treatment

29. America Cancer Society. Cervical Cancer Surgery | How to Remove Cervical Cancer | American Cancer Society [Internet]. 2024 [cited 2025 Apr 14]. Cited from: https://www.cancer.org/cancer/types/cervical-cancer/treating/surgery.html

30. Cervical Cancer Radiation Therapy | Cervical Cancer Radiation Treatment | American Cancer Society [Internet]. [cited 2025 Apr 16]. Cited from: https://www.cancer.org/cancer/types/cervical-cancer/treating/radiation.html

31. Radiation Therapy for Cancer - NCI [Internet]. [cited 2025 Apr 24]. Cited from: https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy

32. Radiation Therapy for Cancer: How Does It Work? [Internet]. [cited 2025 Apr 24]. Cited from: https://my.clevelandclinic.org/health/treatments/17637-radiation-therapy

33. Zhang J, Sun M, Li N, Miao M, Yang Y, Hsu HC, et al. Contemporary external beam radiotherapy boost or high dose-rate brachytherapy boost for cervical cancer: a propensity-score-matched, nationwide, population-based cohort study. Am J Cancer Res [Internet]. 2021 Nov 22 [cited 2025 Apr 24];11(4):1719. Cited from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8085872/

34. Naorem R, Rangasamy K, Ghogale KS, Waghmare CM. Can intensity modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) replace consolidation brachytherapy in the curative treatment of cervical cancer? A dosimetric study. Cancer Res Stat Treat. 2023 Apr 1;6(2):311–5.

35. Benveniste MF, Gomez D, Carter BW, Betancourt Cuellar SL, Shroff GS, Benveniste APA, et al. Recognizing radiation therapy– related complications in the chest. Radiographics [Internet]. 2019 Mar 1 [cited 2025 Apr 24];39(2):344–66. Cited from: https://pubs.rsna.org/doi/10.1148/rg.2019180061

36. Pediatric Oncology Education Materials (POEM). Radiation Therapy (RT) Basics [Internet]. [cited 2025 Apr 24]. Cited from: http://www.pedsoncologyeducation.com/XRTDosimetryBeamArrange.asp

37. Bosque MÁS Del, Cervantes-Bonilla MÁ, Palacios-Saucedo G del C. Clinical and dosimetric factors associated with the development of

hematologic toxicity in locally advanced cervical cancer treated with chemotherapy and 3D conformal radiotherapy. Reports Pract Oncol Radiother. 2018 Sep 1;23(5):392–7.

38. Intensity-Modulated Radiation Therapy (IMRT). 2025 [cited 2025 Apr 24]; Cited from: www.oncolink.org

39. IMRT Planning Process: Fluence Map Optimization – Matthew Davison [Internet]. [cited 2025 Apr 24]. Cited from: https://www.lancaster.ac.uk/stor-i-student-sites/matthew-davison/2021/04/03/imrt-planning-process-fluence-map-optimization/

40. Cobalt-60 | Radiation Emergencies | CDC [Internet]. [cited 2025 Apr 24]. Cited from: https://www.cdc.gov/radiation-emergencies/hcp/isotopes/cobalt-60.html

41. Qomariyah N, Haryanto F, Waris A, Wirawan R, Subroto R, Wayan I, et al. Modeling of Head Linear Accelerator (LINAC) for Study of Photon Beam Characteristics Based on GEANT4. 2023;10(1):6–12.

42. Adams EJ, Warrington AP. A comparison between cobalt and linear accelerator-based treatment plans for conformal and intensity-modulated radiotherapy. Br J Radiol [Internet]. 2008 Apr [cited 2025 Apr 24];81(964):304–10. Cited from: https://pubmed.ncbi.nlm.nih.gov/18250119/

43. Schmitt G, Glaeser L, Kotsch E. Advantages and disadvantages of a 5.7 MeV linear accelerator compared to a 60Co-unit [Internet]. Vol. 154. 1978 [cited 2025 Apr 24]. p. 257–60. Cited from: https://inis.iaea.org/records/p8efq-dhd27

44. Choi CH, Kim JH, Kim J in, Park JM. Comparison of treatment plan quality among MRI-based IMRT with a linac, MRI-based IMRT with tri-Co-60 sources, and VMAT for spine SABR. PLoS One [Internet]. 2019 Jul 1 [cited 2025 Apr 24];14(7). Cited from: https://pubmed.ncbi.nlm.nih.gov/31329641/

45. Aguilar DM, de la Rosa AP, Román EHS, Vilchis AB, Gómez FR, Yudiche AC. Cobalt-60 Radiotherapy Units, Assessment of the Utilization or Disinvestment in Latin America. IFMBE Proc. 2019 Jan 1;68(3):407–12.

46. Zaki P, Sengupta B, Oh K, Cardenas C, Court LE, Ford EC. Cobalt Compensator-Based IMRT for Gynecologic Cancer Treatment in Low- and Middle-Income Countries: Equivalence to LINAC-Based IMRT. Int J Radiat Oncol Biol Phys. 2023 Oct 1;117(2S):S81.

47. Cadman P. An investigation of beam parameters for Co-60 tomotherapy. Med Phys. 2007 Oct 1;34(10):3838–43.

48. Joshi CP, Darko J, Vidyasagar PB, Schreiner LJ. Investigation of an efficient source design for Cobalt-60-based tomotherapy using EGSnrc Monte Carlo simulations. Phys Med Biol. 2008 Feb 7;53(3):575–92.

49. The Benefits of Cobalt-60 (Co-60) for Cancer Therapy [Internet]. [cited 2025 Apr 24]. Cited from: https://www.siloamhospitals.com/en/informasi-siloam/artikel/the-benefits-of-cobalt-60-co-60-for-cancer-therapy

50. Benkhaled S, Diakité K, Jullian N, Poeta S, Vandekerkhove C, Van Houtte P, et al. Boost modalities in cervical cancer: dosimetric comparison between intracavitary BT vs. intracavitary + interstitial BT vs. SBRT. Radiat Oncol [Internet]. 2023 Jun 28 [cited 2025 Apr 24];18(1). Cited from: http://creativecommons.org/publicdomain/zero/1.0/

51. Dahbi Z, Fadila K, Vinh-Hung V. Brachytherapy Versus Stereotactic Body Radiotherapy for Cervical Cancer Boost: A Dosimetric Comparison. Cureus. 2023 Apr 1;15.

52. Muhammad S, Wahyuni Z. Differences in Response to External Radiotherapy and Brachytheraphy as a Booster of Cervical Cancer Management. Indones J Obstet Gynecol Sci. 2024 Mar 20;7(1):53.

53. Gao J, Xu B, Lin Y, Xu Z, Huang M, Li X, et al. Stereotactic Body Radiotherapy Boost with the CyberKnife for Locally Advanced Cervical Cancer: Dosimetric Analysis and Potential Clinical Benefits. Cancers (Basel). 2022 Oct 1;14(20):5166.

54. Al Feghali KA, Elshaikh MA. Why brachytherapy boost is the treatment of choice for most women with locally advanced cervical carcinoma? Brachytherapy [Internet]. 2016 Mar 1 [cited 2025 Apr 25];15(2):191–9. Cited from: https://pubmed.ncbi.nlm.nih.gov/26810408/

55. Campitelli M, Lazzari R, Piccolo F, Ferrazza P, Marsella AR, MacChia G, et al. Brachytherapy or external beam radiotherapy as a boost in locally advanced cervical cancer: a Gynaecology Study Group in the Italian Association of Radiation and Clinical Oncology (AIRO) review. Int J Gynecol Cancer. 2021 Feb 25;31(9):1278–86.

56. Cervical Cancer Chemotherapy | Chemo for Cervical | American Cancer Society [Internet]. [cited 2025 Apr 16]. Cited from: https://www.cancer.org/cancer/types/cervical-cancer/treating/chemotherapy.html

57. Cervical Cancer Targeted Therapy | Targeted Drugs for Cervical Cancer | American Cancer Society [Internet]. [cited 2025 Apr 16]. Cited from: https://www.cancer.org/cancer/types/cervical-cancer/treating/targeted-therapy.html

58. Cervical Cancer Immunotherapy | Immune Checkpoint Inhibitors | American

Cancer Society [Internet]. [cited 2025 Apr 16]. Cited from: https://www.cancer.org/cancer/types/cervical-cancer/treating/immunotherapy.html

59. Belkić K, Andersson S, Alder S, Mints M, Megyessi D. Predictors of treatment failure for adenocarcinoma in situ of the uterine cervix: Up to 14 years of recorded follow-up. Oncol Lett. 2022;24(4):1–13.

60. Hashim D, Engesæter B, Skare GB, Castle PE, Bjørge T. Real-world data on cervical cancer risk strati fi cation by cytology and HPV genotype to inform the management of HPV-positive women in routine cervical screening. Br J Cancer [Internet]. 2020;(August 2019). Cited from: http://dx.doi.org/10.1038/s41416-020-0790-1

61. Dave K KA. Retrospective evaluation of recurrence after radical abdominal hysterectomy in patients with cervical carcinoma [Internet]. Eur J Gynaecol Oncol. 1990 [cited 2025 Apr 26]. p. 11(1):67-73. Cited from: https://pubmed.ncbi.nlm.nih.gov/2347337/

62. Lim S, Lee S ho, Lee KB, Park C yong. The influence of number of high risk factors on clinical outcomes in patients with early-stage cervical cancer after radical hysterectomy and adjuvant chemoradiation. 2016;59(3):184–91.

63. Tian X, Liu P, Kang S, Cui Z, Sun L, Lang J, et al. Impact of histological subtypes on clinical outcome of endocervical adenocarcinoma. Eur J Surg Oncol. 2024 Apr 1;50(4).

64. Kang JH, Cho WK, Yeo HJ, Jeong SY, Noh JJ, Shim JI, et al. Prognostic significance of tumor regression rate during concurrent chemoradiotherapy in locally advanced cervix cancer: Analysis by radiation phase and histologic type. J Clin Med. 2020 Nov 1;9(11):1–13.

65. Gallardo-Alvarado L, Cantú-de León D, Ramirez-Morales R, Santiago-Concha G, Barquet-Muñoz S, Salcedo-Hernandez R, et al. Tumor histology is an independent prognostic factor in locally advanced cervical carcinoma: A retrospective study. BMC Cancer. 2022 Dec 1;22(1).

66. Braik D, Alqaisi H, Garg V, Soberanis Pina P, Valente Lage L, Veneziani A, et al. Molecular characterization of cervical cancer histological subtypes: The VENUS study. J Clin Oncol. 2024 Jun 1;42(16_suppl):5537.

67. Taarnhøj GA, Christensen IJ, Lajer H, Fuglsang K. Risk of Recurrence , Prognosis , and Follow-Up for Danish Women With Cervical Cancer in 2005-2013 : A National Cohort Study. 2018;943–51.

68. Antonius PA, Winarto H. Small cell neuroendocrine carcinoma of the uterine cervix (SCNEC): a case report and review. J Ilmu Kesehat Indones [Internet]. 2021 Jul 30 [cited 2025 Apr 27];2(1):203–6. Cited from: https://www.researchgate.net/publication/360683645_Small_cell_neuroend

ocrine_carcinoma_of_the_uterine_cervix_SCNEC_a_case_report_and_review

69. Isla-Ortiz D, Palomares-Castillo E, Mille-Loera JE, Ramírez-Calderón N, Mohar-Betancourt A, Meneses-García AA, et al. Cervical Cancer in Young Women: Do They Have a Worse Prognosis? A Retrospective Cohort Analysis in a Population of Mexico. Oncologist. 2020 Sep 1;25(9):e1363–71.

70. Zeng J, Zuo J, Li N, Yao HW, Zhang YY, Zhao YX, et al. Clinical analysis of 312 patients with stage IB1-IIA2 cervical squamous cell carcinoma and research on the influencing factors of postoperative recurrence. BMC Womens Health [Internet]. 2023 Feb 23 [cited 2025 Apr 17];23(1). Cited from: http://creativecommons.org/publicdomain/zero/1.0/

71. Wang J, Wang T, Yang YY, Chai YL, Shi F, Liu Z. Patient age, tumor appearance and tumor size are risk factors for early recurrence of cervical cancer. Mol Clin Oncol. 2015 Mar 1;3(2):363–6.

72. Lybeert MLM, Meerwaldt JH, van Putten WLJ. Age as a prognostic factor in carcinoma of the cervix. Radiother Oncol. 1987 Jun 1;9(2):147–51.

73. Jiao S, Guo L, Da F, Gao Q, Ren Z, Wang J, et al. Competitive Risk Model Nomogram to Predict Prognosis in Patients Aged Over 65 Years with nonmetastatic Cervical Cancer: A SEER Population-Based Study. Technol Cancer Res Treat. 2023 Jan 1;22:153303382311641.

74. Zemni I, Aloui M, Boujelbene N, Sakhri S, Zidi I, Ayadi MA, et al. 397 Locally advanced cervical cancer in elderly women. 2024 Mar 1;A90.2-A90.

75. Jina LI, Jiayou LUO, Gaoming LIU, Shipeng YAN. Influencing factors and risk prediction model for cervical cancer recurrence. J Cent South Univ Med Sci. 2022 Dec 28;47 12(12):1711–20.

76. Li J, Liu G, Luo J, Yan S, Ye P, Wang J, et al. Cervical Cancer Recurrence, Prognosis, And Related Risk Factors For Patients With Cervical Cancer: A Long-Term Prospective Cohort Study. 2022 Mar 3;

77. Ntuli L, Mtshali A, Mzobe G, Liebenberg LJP, Ngcapu S. Role of Immunity and Vaginal Microbiome in Clearance and Persistence of Human Papillomavirus Infection. Front Cell Infect Microbiol. 2022 Jul 7;12.

78. Bruno MT, Caruso S, Scalia G, Costanzo M, Di Pasqua S, Boemi S, et al. Papillomavirus Infection as Potential Cause of Miscarriage in the Early Gestational Age: A Prospective Study. Diagnostics. 2023 May 1;13(9):1659.

79. Dedousi D, Potiris A, Zikopoulos A, Karampitsakos T, Topis S, Skentou C, et al. The Impact of Human Papillomavirus Infections on Recurrent Pregnancy Loss: A Review of the Literature. Diseases. 2024 Sep

13;12(9):214.

80. Ten Eikelder MLG, Hinten F, Smits A, Van der Aa MA, Bekkers RLM, Inthout J, et al. Does the New FIGO 2018 Staging System Allow Better Prognostic Differentiation in Early Stage Cervical Cancer? A Dutch Nationwide Cohort Study. Cancers (Basel). 2022 Jun 27;14(13):3140–3140.

81. Liu X, Wang W, Hu K, Zhang F, Hou X, Yan J, et al. A Risk Stratification for Patients with Cervical Cancer in Stage IIIC1 of the 2018 FIGO Staging System. Sci Rep. 2020 Jan 15;10(1):362.

82. Halle MK, Bozickovic O, Forsse D, Wagner-Larsen KS, Gold RM, Lura NG, et al. Clinicopathological and radiological stratification within FIGO 2018 stages improves risk-prediction in cervical cancer. Gynecol Oncol. 2023 Dec 26;181:110–7.

83. Widhiarta PR, Mahendra INB, Aryana MBD, Megaputra IG. Faktor-faktor klinikopatologi Kekambuhan Kanker Serviks Stadium I-IIA2 Pasca Histerektomi Radikal di RSUP Sanglah Periode 2017 – 2018. J Intisari Sains Medis. 2021;12(1):196–200.

84. Ayhan A, Al RA, Baykal C, Demirtas E, Ayhan A, Yüce K. Prognostic factors in FIGO stage IB cervical cancer without lymph node metastasis and the role of adjuvant radiotherapy after radical hysterectomy. Int J Gynecol Cancer. 2004 Mar 1;14(2):286–92.

85. Singh P, Tripcony L, Nicklin J. Analysis of prognostic variables, development of predictive models, and stratification of risk groups in surgically treated FIGO early-stage (IA-IIA) carcinoma cervix. Int J Gynecol Cancer. 2012 Jan 1;22(1):115–22.

86. Artuso V, Meschini T, Schivardi G, Vitis LA De, Multinu F, Martin-Calvo N, et al. #666 Predictors of recurrence in surgically staged intermediate-risk early-stage cervical cancer. 2023 Sep 1;A87.2-A88.

87. Hoskins WJ. 8 Prognostic factors for risk of recurrence in stages Ib and IIa cervical cancer. Best Pract Res Clin Obstet Gynaecol. 1988 Dec 1;2(4):817–28.

88. Chang CS, Min JS, Song KH, Choi CH, Kim TJ, Lee JW, et al. The Role of Conization before Radical Hysterectomy in Cervical Cancer including High Risk Factors of Recurrence: Propensity Score Matching. Cancers (Basel). 2022 Aug 1;14(16):3863.

89. Llueca A, Ibañez MV, Torne A, Gil-Moreno A, Martin-Jimenez A, Diaz-Feijoo B, et al. Fertility-Sparing Surgery versus Radical Hysterectomy in Early Cervical Cancer: A Propensity Score Matching Analysis and Noninferiority Study. J Pers Med. 2022 Jun 30;12(7):1081.

90. Gouy S, Scherier S, Maulard A, Zaccarini F, Zarokian J, Sanson C, et al. 2022-RA-181-ESGO Updated systematic review about results of fertility sparing surgery of cervical cancer. 2022 Oct 1;A2.3-A3.

91. Murakami I, Tanaka K. Fertility-Sparing Treatment of Early and Locally Advanced Cervical Cancer. Compr Gynecol Obstet. 2024 Jan 1;135–47.

92. Ou X, You J, Liang B, Li X, Zhou J, Wen F, et al. Prognostic Factors Analysis of Metastatic Recurrence in Cervical Carcinoma Patients Treated with Definitive Radiotherapy: A Retrospective Study Using Mixture Cure Model. Cancers (Basel). 2023 May 25;15(11):2913–2913.

93. de Foucher T, Bendifallah S, Ouldamer L, Bricou A, Lavoue V, Varinot J, et al. Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer: Retrospective multicentre study from the FRANCOGYN group. Eur J Surg Oncol. 2019 Apr 1;45(4):659–65.

94. Slama J, Runnebaum IB, Scambia G, Angeles MA, Bahrehmand K, Kommoss S, et al. Analysis of risk factors for recurrence in cervical cancer patients after fertility-sparing treatment: The FERTIlity Sparing Surgery retrospective multicenter study. Am J Obstet Gynecol. 2023 Apr 1;228(4):443.e1-443.e10.

95. Ma GF, Lin GL, Wang ST, Huang YY, Xiao CL, Sun J, et al. Prediction of recurrence-related factors for patients with early-stage cervical cancer following radical hysterectomy and adjuvant radiotherapy. BMC Womens Health. 2024 Jan 31;24(1).

96. Jaggi VK, Ansari MA, Khanna A, Gehlot S, Sharma A, Singh K. Is postoperative radiotherapy (PORT) a viable option in high-risk early-stage cervical cancer after upfront or downstaged radical surgery? A comparative study. J Cancer Res Ther [Internet]. 2023 Jan 1 [cited 2025 Sep 13];19(2):241–52. Cited from: https://journals.lww.com/cancerjournal/fulltext/2023/19020/is_postoperative_radiotherapy__port__a_viable.16.aspx

97. Wang H, Ni C, Xiao W, Yang T, Sun W. Comparison of Radical Surgery and Radiotherapy for the Treatment of Early-Stage Cervical Carcinoma: A Meta-Analysis. Oncol Res Treat [Internet]. 2021 Mar 1 [cited 2025 Sep 13];44(4):176–83. Cited from: https://pubmed.ncbi.nlm.nih.gov/33706315/

98. Lim YJ, Lee HN. Optimal use of radiotherapy in the definitive treatment of non-bulky IB–IIA cervical cancer: A population-based long-term survival analysis. PLoS One [Internet]. 2021 Jun 1 [cited 2025 Sep 13];16(6):e0253649. Cited from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0253649

99. Yetmen Dogan O, Sahinler I. Comparison of Chemoradiotherapy and Radical Radiotherapy in Patients With Cervical Cancer. Multidiscip Cancer

Investig [Internet]. 2020 Mar 1 [cited 2025 Sep 13];4(2):15–20. Cited from: http://mcijournal.com/article-1-259-en.html

100. Huang Z, Yao W, Zhong Z, Yang G, Liu J, Gu H, et al. Chemotherapy alone versus chemotherapy plus 125I brachytherapy for the second-line treatment of locally recurrent cervical cancer after/with radical treatment: A propensity score analysis. Heliyon [Internet]. 2024 Jan 30 [cited 2025 Sep 13];10(2):e24666. Cited from: https://www.sciencedirect.com/science/article/pii/S2405844024006972

101. Li L, Kou XX, Feng XJ, Zhang MC, Chao HT, Wang LY. Postoperative external beam irradiation with and without brachytherapy in pelvic node-positive IB1-IIA2 cervical cancer patients: A retrospective clinical study. Radiat Oncol [Internet]. 2015 Sep 17 [cited 2025 Apr 24];10(1):1–6. Cited from: https://ro-journal.biomedcentral.com/articles/10.1186/s13014-015-0495-4

102. Delgado D, Figueiredo A, Mendonça V, Jorge M, Abdulrehman M, De Pina MF. Results from chemoradiotherapy for squamous cell cervical cancer with or without intracavitary brachytherapy. J Contemp Brachytherapy. 2019 Oct 1;11(5):417–22.

103. Lee HC, Jeong JW, Lee JH, Kim SH, Park DC, Yoon JH, et al. High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial. Gynecol Oncol. 2023 Oct 1;177:142–9.

104. Zhang J, Hsu HC, Chen HM, Wu SY. Contemporary External Beam Radiotherapy Boost or High Dose-Rate Brachytherapy Boost for Cervical Cancer: A Propensity-Score–Matched, Nationwide, Population-Based Cohort Study. Soc Sci Res Netw. 2020 Nov 11;

105. Ager BJ, Torgeson A, Francis SR, Burt LM, Gaffney DK, Cannon DM. Impact of Brachytherapy Boost and Dose-escalated External Beam Radiotherapy in Margin Positive Cervical Cancer Treated With Chemotherapy and Radiation. Am J Clin Oncol. 2020 Jan 1;43(1):35–42.

106. Haris Suhartono B, Setia Budi W, Eko Hidayanto dan. Distribusi Dosis Photon Menggunakan Teknik 3DCRT dan IMRT pada Radiasi Whole Pelvic Karsinoma Serviks. 2014;17(4):121–8.

107. View of Analisis Treatment Planning System dengan Menggunakan Teknik Box dan Teknik Antero Posterior-Postero Anterior pada Kasus Kanker Serviks [Internet]. [cited 2025 Apr 11]. Cited from: https://jurnal.fmipa.unmul.ac.id/index.php/ppj/article/view/873/410

108. Thakur P, Revannasiddaiah S, Rastogi M, Gupta MK, Seam RK, Gupta M. Uncertainty concerning the 4-field box technique for Stage-IB2 carcinoma of the uterine cervix. J Med Phys [Internet]. 2013 Jan [cited 2025 Apr

11];38(1):41. Cited from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3607345/

109. Li R, Keall P, Xing L. Linac-Based Image Guided Intensity Modulated Radiation Therapy. 2011 Jan 1;275–312.

110. Jiang D, Yang C, Sun S, Wang D, Xiao Z, Hu J, et al. First implementation and results of online adaptive radiotherapy for cervical cancer based on CT-Linac combination. Front Oncol. 2024 Nov 14;14.

111. Fox C, Romeijn HE, Lynch B, Men C, Aleman DM, Dempsey JF. Comparative analysis of 60Co intensity-modulated radiation therapy. Phys Med Biol. 2008 Jun 21;53(12):3175–88.

112. Dhanesar SK, Darko J, Joshi CP, Kerr A, Schreiner LJ. SU-EE-A1-06: A Comparative Study of Cobalt-60 Based Tomotherapy versus 6 MV Linac-Based Tomotherapy, IMRT, and 3DCRT for the Treatment Planning of Prostate and Head and Neck Cases. Med Phys. 2010 Jun 1;37(6):3095–3095.

113. Poffenbarger BA, Podgorsak EB. Viability of an isocentric cobalt-60 teletherapy unit for stereotactic radiosurgery. Med Phys. 1998 Oct 1;25(10):1935–43.

114. Dhanesar S, Darko J, Joshi CP, Kerr A, John Schreiner L. Cobalt-60 tomotherapy: Clinical treatment planning and phantom dose delivery studies. Med Phys. 2013 Aug 1;40(8):081710.

115. Genetics M, Sciences B, Sciences M. Review Therapeutic resistance and cancer recurrence mechanisms : Unfolding the story of tumour coming back. 2015;

116. Pavone G, Marino A, Fisicaro V, Motta L, Spata A, Martorana F, et al. Entangled Connections: HIV and HPV Interplay in Cervical Cancer—A Comprehensive Review. Int J Mol Sci. 2024 Sep 26;25(19):10358–10358.

117. Thomas DS, Thomas V, Sebastian A, Thomas A, Abraham P, Chandy R, et al. HPV DNA Detection for Post-treatment Surveillance of Premalignant and Malignant Lesions of Cervix. Indian J Gynecol Oncol. 2020 Mar 1;18(1):1–7.

118. Sabeena S, Kuriakose S, Damodaran B, Ravishankar N, Arunkumar G. Human papillomavirus (HPV) DNA detection in uterine cervix cancer after radiation indicating recurrence: a systematic review and meta-analysis. J Gynecol Oncol. 2020 Jan 17;31(2):20.

119. Song YJ, Kim JY, Lee SK, Lim HS, Lim MC, Seo SS, et al. Persistent human papillomavirus DNA is associated with local recurrence after radiotherapy of uterine cervical cancer. Int J Cancer. 2011 Aug 15;129(4):896–902.

120. Zhang Y, Ni Z, Wei T, Liu Q. Persistent HPV infection after conization of cervical intraepithelial neoplasia—— a systematic review and meta-analysis. BMC Womens Health [Internet]. 2023 May 3 [cited 2025 Apr 19];23(1). Cited from: http://creativecommons.org/publicdomain/zero/1.0/

121. Salarzaei M, van de Laar RLO, Ewing-Graham PC, Najjary S, van Esch E, van Beekhuizen HJ, et al. Unraveling Differences in Molecular Mechanisms and Immunological Contrasts between Squamous Cell Carcinoma and Adenocarcinoma of the Cervix. Int J Mol Sci. 2024 Jun 1;25(11).

122. Liu B, Xu Y, Hu B, Song X, Lin S, Wang J, et al. Immune landscape and heterogeneity of cervical squamous cell carcinoma and adenocarcinoma. Aging (Albany NY). 2024;16(1):568–92.

123. Uke A, Dahake SB, Luharia A, Luharia M, Mishra G V, Mahakalkar C. Investigating and Analyzing Prognostic Factors and Their Impact on Recurrent Cervical Cancers. Cureus. 2024 Jul 25;

124. Manzour N, Chacon E, Martín-Calvo N, Mínguez JÁ, Castellano T, Vazquez D, et al. 258 Design and validation of a recurrence risk predicting score in early stage cervical cancer after radical hysterectomy. 2020 Dec 1;30:A8.1-A8.

125. Ashrafyan LA, Belokrinitskaya TE, Sholokhov LF, Kayukova E V., Mudrov VA. The recurrences of cervical cancer: Possibilities of molecular prediction. Acta Biomed Sci. 2022 May 21;7(2):34–41.

126. Chen W, Xia X, Xie X, Wei Y, Wu R, Cai W, et al. Nomogram for prognosis of elderly patients with cervical cancer who receive combined radiotherapy. 2022 Dec 14;

127. Hopkins JF, Sabelnykova VY, Weischenfeldt J, Simon R, Aguiar JA, Alkallas R, et al. Mitochondrial mutations drive prostate cancer aggression. Nat Commun 2017 81 [Internet]. 2017 Sep 22 [cited 2025 Apr 26];8(1):1–8. Cited from: https://www.nature.com/articles/s41467-017-00377-y

128. Hinkula M, Pukkala E, Kyyrönen P, Laukkanen P, Koskela P, Paavonen J, et al. A population-based study on the risk of cervical cancer and cervical intraepithelial neoplasia among grand multiparous women in Finland. Br J Cancer. 2004 Mar 8;90(5):1025–9.

129. Wyllie DA. Role of parity and HPV in cervical cancer: the IARC muticentric case-control study. Munoz N, Franceschi S, Bosetti C, et al. Lancet 2002; 399(9312): 1093-1101. J Fam Plan Reprod Heal Care. 2002 Jul 1;28(3):164.

130. Oga EA, Brown JP, Brown C, Dareng E, Adekanmbi V, Odutola M, et al. Recurrence of cervical intraepithelial lesions after thermo-coagulation in HIV-positive and HIV-negative Nigerian women. BMC Womens Health. 2016;16(1).

131. Gao B, Zhao X, Liu X, Yang X, Zhang A, Huang H, et al. Imbalance of the Gut Microbiota May Be Associated with Missed Abortions: A Perspective Study from a General Hospital of Hunan Province. J Immunol Res [Internet]. 2021 [cited 2025 Apr 26];2021:5571894. Cited from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8712186/

132. Wang Y, Chen Y, Wang M, Qin Z, Zhang L, Zheng A, et al. Oncological and reproductive outcomes of conization combined with pelvic node evaluation in patients with early-stage cervical cancer: a systematic review and meta-analysis. Front Oncol. 2023 Sep 19;13.

133. Li Y, Chen Z, Wang X, Li X, Zhou J, Zhang Y. Clinical outcomes observation in stage IIB–IIIB cervical cancer treated by adjuvant surgery following concurrent chemoradiotherapy. BMC Cancer [Internet]. 2021 Dec 1 [cited 2025 Sep 13];21(1):442. Cited from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8059156/

134. S MI, Milvita D, Ilyas M. Analisis Perencanaan Radioterapi Menggunakan Teknik Intensity Modulated Radiotherapy (IMRT) pada Pasien Kanker Serviks. J Fis Unand. 2023;12(1):164–70.

135. Lakshmi Arumdalu K, Moh. Nailul Fahmi NA. The Association of Lymphovascular Space Invasion (LVSI) and Stage of Disease in Epithelial Ovarian Carcinoma Patients in RSUP Dr. Sardjito Yogyakarta LAKSMI ARUMDALU K, dr. Moh, Nailul Fahmi, Sp.OG; dr. Nungki Anggorowati, Sp.PA., Ph.D. 2022;1–2. Cited from: http://etd.repository.ugm.ac.id/

136. Reich O, Regauer S. Elimination of reserve cells for prevention of HPV-associated cervical cancer. Virus Res. 2023 May;329:199068.

137. Kusuma R. Derajat Differensiasi Histopatologik pada Kejadian Rekurensi Kanker Serviks. 2009 [cited 2025 Oct 19]; Cited from: http://www.fk.undip.ac.id

138. Yoder AK, Dong E, Yu X, Echeverria A, Sharma S, Montealegre J, et al. Impact of Quality of Life on Radiation Adherence for Cervical Cancer Patients in an Urban Safety Net Health System: Quality of Life and Radiation Adherence. Int J Radiat Oncol Biol Phys [Internet]. 2022 May 1 [cited 2025 Oct 24];116(1):182. Cited from: https://pmc.ncbi.nlm.nih.gov/articles/PMC10083186/